StockData
AnaptysBio, Inc logo

AnaptysBio, Inc (ANAB) stock

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30
$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $2.28BP/E –Yield –

AnaptysBio r&d expenses

Research and development expenses are spending on new products and technology.

AnaptysBio's R&D Expenses for the twelve months ending Mar 31, 2026 was $128.78M, down 23.3% year over year. For fiscal 2025 it was $135.97M, down 17.0% from the year before. Over ten years it grew 22.9% a year on average. The highest annual figure on record is $163.84M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$135.97M-17.0%
FY2024Dec 31, 2024$163.84M+23.9%
FY2023Dec 31, 2023$132.28M+49.0%
FY2022Dec 31, 2022$88.80M-9.8%
FY2021Dec 31, 2021$98.50M+23.1%
FY2020Dec 31, 2020$80.03M-19.4%
FY2019Dec 31, 2019$99.34M+76.8%
FY2018Dec 31, 2018$56.20M+90.9%
FY2017Dec 31, 2017$29.44M+91.0%
FY2016Dec 31, 2016$15.42M-10.9%
FY2015Dec 31, 2015$17.30M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$33.99M-17.5%
Q4 FY2025Dec 31, 2025$25.56M-40.0%
Q3 FY2025Sep 30, 2025$31.41M-25.6%
Q2 FY2025Jun 30, 2025$37.82M-9.9%
Q1 FY2025Mar 31, 2025$41.18M+11.2%
Q4 FY2024Dec 31, 2024$42.59M+27.0%
Q3 FY2024Sep 30, 2024$42.21M+36.7%
Q2 FY2024Jun 30, 2024$42.00M+27.6%
Q1 FY2024Mar 31, 2024$37.04M+6.0%
Q4 FY2023Dec 31, 2023$33.53M+43.4%
Q3 FY2023Sep 30, 2023$30.88M+39.9%
Q2 FY2023Jun 30, 2023$32.92M+57.9%
Q1 FY2023Mar 31, 2023$34.96M+55.3%
Q4 FY2022Dec 31, 2022$23.37M-12.7%
Q3 FY2022Sep 30, 2022$22.06M-0.7%
Q2 FY2022Jun 30, 2022$20.84M-17.7%
Q1 FY2022Mar 31, 2022$22.52M-6.9%
Q4 FY2021Dec 31, 2021$26.78M+24.2%
Q3 FY2021Sep 30, 2021$22.22M+13.7%
Q2 FY2021Jun 30, 2021$25.31M+41.0%
Q1 FY2021Mar 31, 2021$24.19M+15.3%
Q4 FY2020Dec 31, 2020$21.57M+0.7%
Q3 FY2020Sep 30, 2020$19.54M-34.7%
Q2 FY2020Jun 30, 2020$17.95M-34.4%
Q1 FY2020Mar 31, 2020$20.97M+1.6%
Q4 FY2019Dec 31, 2019$21.43M+34.6%
Q3 FY2019Sep 30, 2019$29.93M+67.4%
Q2 FY2019Jun 30, 2019$27.35M+158.4%
Q1 FY2019Mar 31, 2019$20.63M+74.7%
Q4 FY2018Dec 31, 2018$15.92M+109.3%
Q3 FY2018Sep 30, 2018$17.88M+167.0%
Q2 FY2018Jun 30, 2018$10.58M+46.9%
Q1 FY2018Mar 31, 2018$11.81M+48.8%
Q4 FY2017Dec 31, 2017$7.61M+51.6%
Q3 FY2017Sep 30, 2017$6.70M+104.1%
Q2 FY2017Jun 30, 2017$7.21M–
Q1 FY2017Mar 31, 2017$7.94M–
Q4 FY2016Dec 31, 2016$5.02M–
Q3 FY2016Sep 30, 2016$3.28M–

More AnaptysBio figures

See a number that looks wrong?